Lexicon converts all preferred to 115M common; authorized shares increased to 450M

LEXICON PHARMACEUTICALS, INC.

2,304,147 shares of Series A Preferred automatically converted into 115,207,350 common shares on May 10, 2024.
Authorized common stock increased from 300M to 450M via Sixth Amended and Restated Certificate of Incorporation.
Stockholders elected Philippe Amouyal, Lonnel Coats, and Diane Sullivan as Class III directors with >241M votes each.
Ratified charter amendment, approved executive compensation, and reappointed Ernst & Young as auditor for FY2024.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

LEXICON PHARMACEUTICALS, INC.: Amended and restated certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares (effective 2024-05-10).

Change: charter amendment
Effective: 2024-05-10

Exact text from the filing

On May 10, 2024, we filed a Sixth Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware, which became effective on the filing date. The Sixth Amended and Restated Certificate of Incorporation increases the number of shares of our authorized Common Stock from 300,000,000 to 450,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LEXICON PHARMACEUTICALS, INC. shareholders approved Election of Class III Directors at the 2024-05-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-10

Exact text from the filing

(1) Election of Class III Directors Name of Director For Withheld Broker Non-Votes Philippe J. Amouyal 241,812,501 18,607,732 29,015,729

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024 at the 2024-05-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-10

Exact text from the filing

(4) Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2024 286,136,766 2,884,465 414,731

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LEXICON PHARMACEUTICALS, INC. shareholders approved Ratification and approval of the Company's Sixth Amended and Restated Certificate of Incorporation at the 2024-05-10 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2024-05-10

Exact text from the filing

(2) Ratification and approval of the the Company’s Sixth Amended and Restated Certificate of Incorporation 160,676,391 1,433,806 211,035

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

LEXICON PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve the compensation paid to the Company's named executive officers at the 2024-05-10 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-05-10

Exact text from the filing

(3) Advisory vote to approve the compensation paid to the Company’s named executive officers 253,593,322 6,203,593 623,318

View on SEC.gov

247 governance changes filed in the last 30 days. Browse all governance changes →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.